Costing and cost analysis in randomized controlled trials: Caveat emptor

PharmacoEconomics

Volumn 27, Issue 3, 2009, Pages 179-188

  Polsky, Daniel ^a   Glick, Henry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTIC METHOD; ARTICLE; COST; COST BENEFIT ANALYSIS; HOSPITALIZATION; LABORATORY TEST; MEDICAL SERVICE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

COSTS AND COST ANALYSIS; DRUG COSTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 64749104061     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927030-00001     Document Type: Article

References (45)

1. Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
2. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005
3. Glick HA, Doshi JA, Sonnad SS, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2007
4. Finkler S. The distinction between costs and charges. Ann Int Med 1982; 96: 102-9
5. Medical Research Council Laparoscopic Groin Hernia Trial Group. Cost-utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial, Br J Surg 2001; 88 (5): 653-61
6. Fleming MF, Mundt MP, French MT, et al. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med Care 2000; 38 (1): 7-18
7. Halpern MT, Palmer CS, Zodet M, et al. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am J Health Sys Pharm 2002; 59 (14): 1357-65
8. Simon GE, Manning WG, Katzelnick DJ, et al. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 2001; 58 (2): 181-7
9. Beck EJ, Beecham J, Mandalia S, et al. What is the cost of getting the price wrong? J Public Health Med 1999; 21:311-7
10. Heerey A, McGowan B, Ryan M, et al. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2: 29-33
11. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: how good a basis for estimating costs? Inquiry 1995; 32: 476-81
12. Rittenhouse BE, Dulissec B, Stinnett AA. At what price significance? The effect of price estimates on statistical inference in economic evaluation. Health Econ 1999; 8: 213-19
13. Reed SD, Friedman JY, Gnanasakthy A, et al. Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. Int J Technol Assess Health Care 2003; 19: 395-406
14. Chumney ECG, Biddle AK, Simpson KN, et al. The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios. Pharmacoeconomics 2004; 22 (18): 1209-16
15. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 2003; 145: 452-58
16. Goeree R, Gafni A, Hannah M, et al. Hospital selection for unit cost estimates in multicentre economic evaluations: does the choice of hospitals make a difference? Pharmacoeconomics 1999; 15 (6): 561-72
17. Schulman K, Burke J, Drummond M, et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ 1998; 7: 629-38
18. Glick HA, Orzol SM, Tooley JF, et al. Design and analysis of unit cost estimation studies: how many hospital diagnoses? How many countries? Health Econ 2003; 12: 5.17-27
19. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-200
20. Ramsey S, Willke R, Briggs A, et al. Best practices for economic analysis alongside clinical trials: an ISPOR RCT-CEA Task Force report. Value Health 2005; 8: 521-33
21. Hurley J. An overview of normative economics of the health sector. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics, vol. IA. Amsterdam.: Elsevier Science BV, 2000; 61: 55-118
22. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78: 605-10
23. Gayan AK. Significance of difference between the means of two non-normal samples. Biometrika 1950; 37: 399-408
24. Pearson ES, Please NW. Relation between the shape of population distribution and the robustness of four simple test statistics. Biometrika 1975; 62: 223-41
25. Geary RC. Testing for normality. Biometrika 1947; 36: 353-69
26. Doshi JA, Glick HA, Polsky D. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health 2006; 9 (5): 334-40
27. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ 1998; 17 (3): 247-81
28. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-36
29. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health. Econ 1998; 17 (3): 283-95
30. Davison AC, Hinkley DV. Bootstrap methods and their application. Cambridge: Cambridge University Press, 1997
31. O'Hagan A, Stevens JW. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 2003; 12: 33-49
32. Conigliani C, Tancredi A. Semi-parametric modelling for costs of health care technologies. Stat Med 2005; 24 (20): 3171-84
33. Briggs A, Nixon R, Dixon S, et al. Parametric modelling of cost data: some simulation evidence. Health Econ 2005; 11: 421-28
34. Gail MH, Wieand S, Pianados S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika 1984; 71: 431-44
35. Senn SJ. Covariate imbalance and random allocation in clinical trials. Stat. Med 1989; 8: 467-75
36. Vazquez-Polo FJ, Negrin Hernanez MA, Gonzalez Lopez-Valcarcel B. Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. Health Econ 2005; 14: 545-57
37. Newhous JM. Estimation efficiency with omitted covariates in generalized linear models. J Am Statist Assoc 1998; 93 (443): 1124-29
38. Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centredifferences into cost-effectiveness evaluations. Health Econ 2005; 14: 1217-29
39. Newhous JM, Jewell NP. A geometric approach to assess bias due to omitted covariates in generalized linear models. Biometrika 1993; 80: 807-16
40. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-94
41. Nelder JA, Wedderburn RWM. Generalized linear models. J Roy Statist Soc A 1972; 135: 370-84
42. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman & Hall, 1989
43. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999; 18: 153-71
44. Barber J, Thompson S. Multiple regression of cost data: use of generalized linear models. J Health Serv Res Policy 2004; 9: 197-9
45. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6: 93-109